(CRL) Charles River Laboratories - Overview
Stock: Research Models, Safety Assessment, Manufacturing Testing, Drug Discovery
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 48.5% |
| Relative Tail Risk | -14.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.45 |
| Alpha | -6.54 |
| Character TTM | |
|---|---|
| Beta | 1.430 |
| Beta Downside | 1.677 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.52% |
| CAGR/Max DD | -0.13 |
Description: CRL Charles River Laboratories January 07, 2026
Charles River Laboratories International (NYSE: CRL) delivers outsourced drug-discovery, non-clinical development, and safety-testing services across three core segments: Research Models & Services (RMS), which supplies rodents and genetically engineered animal models plus related support services; Discovery & Safety Assessment (DSA), which provides early-stage target validation, toxicology, pathology, bioanalysis, and pharmacokinetic testing; and Manufacturing Solutions, which offers in-vitro quality-control testing for pharmaceuticals and biologics, as well as contract vivarium operations.
In its most recent fiscal year (2023), CRL reported revenue of approximately $2.9 billion, representing an 8 % year-over-year increase driven largely by higher demand for RMS animal models and DSA toxicology services; operating margin expanded to about 12 % and free cash flow exceeded $400 million, reflecting strong pricing power and efficient cost management. The company’s cash balance topped $1.2 billion, giving it ample runway for strategic acquisitions and R&D investments.
Key macro drivers for the Life Sciences Tools & Services sector include sustained growth in global biotech R&D spend (projected CAGR ≈ 10 % through 2028), an aging population that fuels demand for novel therapeutics, and tighter regulatory timelines that push sponsors toward outsourced pre-clinical capabilities. CRL’s collaborations with the Parker Institute for Cancer Immunotherapy, Children’s Hospital Los Angeles, and the Francis Crick Institute further embed the firm in high-growth therapeutic areas such as immuno-oncology and antibody-drug conjugates.
For a deeper, data-rich assessment of CRL’s valuation dynamics, you may find ValueRay’s analytical platform worth exploring.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -83.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.23 > 1.0 |
| NWC/Revenue: 10.19% < 20% (prev 11.88%; Δ -1.69% < -1%) |
| CFO/TA 0.10 > 3% & CFO 749.5m > Net Income -83.5m |
| Net Debt (2.42b) to EBITDA (516.4m): 4.69 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.4m) vs 12m ago -4.18% < -2% |
| Gross Margin: 32.25% > 18% (prev 0.35%; Δ 3191 % > 0.5%) |
| Asset Turnover: 51.86% > 50% (prev 50.74%; Δ 1.12% > 0%) |
| Interest Coverage Ratio: 0.80 > 6 (EBITDA TTM 516.4m / Interest Expense TTM 111.5m) |
Altman Z'' 1.73
| A: 0.05 (Total Current Assets 1.53b - Total Current Liabilities 1.12b) / Total Assets 7.51b |
| B: 0.26 (Retained Earnings 1.94b / Total Assets 7.51b) |
| C: 0.01 (EBIT TTM 89.3m / Avg Total Assets 7.76b) |
| D: 0.43 (Book Value of Equity 1.75b / Total Liabilities 4.06b) |
| Altman-Z'' Score: 1.73 = BBB |
Beneish M -3.12
| DSRI: 0.98 (Receivables 734.5m/754.2m, Revenue 4.02b/4.06b) |
| GMI: 1.08 (GM 32.25% / 34.76%) |
| AQI: 0.95 (AQ_t 0.53 / AQ_t-1 0.56) |
| SGI: 0.99 (Revenue 4.02b / 4.06b) |
| TATA: -0.11 (NI -83.5m - CFO 749.5m) / TA 7.51b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of CRL shares?
Over the past week, the price has changed by -10.11%, over one month by -12.45%, over three months by +10.73% and over the past year by +13.80%.
Is CRL a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 14
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the CRL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 215.7 | 14% |
| Analysts Target Price | 215.7 | 14% |
| ValueRay Target Price | 195.4 | 3.3% |
CRL Fundamental Data Overview January 31, 2026
P/S = 2.562
P/B = 3.0592
P/EG = 0.1554
Revenue TTM = 4.02b USD
EBIT TTM = 89.3m USD
EBITDA TTM = 516.4m USD
Long Term Debt = 2.19b USD (from longTermDebt, last quarter)
Short Term Debt = 2.64m USD (from shortTermDebt, last quarter)
Debt = 2.63b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.42b USD (from netDebt column, last quarter)
Enterprise Value = 12.73b USD (10.31b + Debt 2.63b - CCE 207.1m)
Interest Coverage Ratio = 0.80 (Ebit TTM 89.3m / Interest Expense TTM 111.5m)
EV/FCF = 23.42x (Enterprise Value 12.73b / FCF TTM 543.7m)
FCF Yield = 4.27% (FCF TTM 543.7m / Enterprise Value 12.73b)
FCF Margin = 13.51% (FCF TTM 543.7m / Revenue TTM 4.02b)
Net Margin = -2.07% (Net Income TTM -83.5m / Revenue TTM 4.02b)
Gross Margin = 32.25% ((Revenue TTM 4.02b - Cost of Revenue TTM 2.73b) / Revenue TTM)
Gross Margin QoQ = 33.72% (prev 34.59%)
Tobins Q-Ratio = 1.69 (Enterprise Value 12.73b / Total Assets 7.51b)
Interest Expense / Debt = 0.97% (Interest Expense 25.4m / Debt 2.63b)
Taxrate = 36.29% (31.6m / 87.2m)
NOPAT = 56.9m (EBIT 89.3m * (1 - 36.29%))
Current Ratio = 1.37 (Total Current Assets 1.53b / Total Current Liabilities 1.12b)
Debt / Equity = 0.77 (Debt 2.63b / totalStockholderEquity, last quarter 3.41b)
Debt / EBITDA = 4.69 (Net Debt 2.42b / EBITDA 516.4m)
Debt / FCF = 4.46 (Net Debt 2.42b / FCF TTM 543.7m)
Total Stockholder Equity = 3.35b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.08% (Net Income -83.5m / Total Assets 7.51b)
RoE = -2.49% (Net Income TTM -83.5m / Total Stockholder Equity 3.35b)
RoCE = 1.61% (EBIT 89.3m / Capital Employed (Equity 3.35b + L.T.Debt 2.19b))
RoIC = 1.00% (NOPAT 56.9m / Invested Capital 5.67b)
WACC = 9.03% (E(10.31b)/V(12.94b) * Re(11.18%) + D(2.63b)/V(12.94b) * Rd(0.97%) * (1-Tc(0.36)))
Discount Rate = 11.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.15%
[DCF Debug] Terminal Value 77.98% ; FCFF base≈550.4m ; Y1≈678.9m ; Y5≈1.16b
Fair Price DCF = 278.9 (EV 16.15b - Net Debt 2.42b = Equity 13.73b / Shares 49.2m; r=9.03% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -45.84 | EPS CAGR: -47.59% | SUE: -4.0 | # QB: 0
Revenue Correlation: 38.38 | Revenue CAGR: 2.83% | SUE: 0.98 | # QB: 5
EPS next Quarter (2026-03-31): EPS=2.58 | Chg30d=-0.013 | Revisions Net=-2 | Analysts=10
EPS next Year (2026-12-31): EPS=10.95 | Chg30d=+0.016 | Revisions Net=+2 | Growth EPS=+7.0% | Growth Revenue=+1.7%